Education
About Us
Working with TipRanks
Follow Us
AddLife AB Class B (SE:ALIF.B)
:ALIF.B
Top Page
AddLife AB
(OTC:ALIF.B)
Rating:60Neutral
Price Target:
kr179.00
▼(-2.03% Downside)
AddLife AB (ALIF.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
$22.05B
Dividend Yield0.41%
Average Volume (3M)69.18K
Price to Earnings (P/E)65.4
Beta (1Y)0.70
Revenue Growth4.56%
EPS Growth185.59%
CountrySE
Employees2,251
SectorHealthcare
Sector Strength53
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.57
Shares Outstanding117,877,460
10 Day Avg. Volume67,791
30 Day Avg. Volume69,182
Financial Highlights & Ratios
PEG Ratio2.03
Price to Book (P/B)3.15
Price to Sales (P/S)1.63
P/FCF Ratio20.97
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda35.70
Forecast
1Y Price Target
$179.96Price Target Upside-1.50% Downside
Rating ConsensusHold
Number of Analyst Covering0
AddLife AB Business Overview & Revenue Model
Company DescriptionAddLife AB (ALIF.B) is a leading Nordic player in the life science sector, focusing on providing products and services primarily to the healthcare and research industries. The company specializes in the distribution of laboratory equipment, diagnostics, and medical technology, catering to a wide range of customers including hospitals, laboratories, and universities. AddLife operates through several business areas, including Life Science, Medical Technology, and Laboratory Products, ensuring a comprehensive portfolio that meets the evolving needs of its clients in the healthcare ecosystem.
How the Company Makes MoneyAddLife AB generates revenue through multiple streams, primarily by selling a diverse range of products in the life sciences and medical technology sectors. Key revenue streams include the sale of laboratory equipment, medical devices, and diagnostic products. The company also earns income from services related to the maintenance and support of medical equipment, as well as consultancy services in life sciences. Additionally, AddLife benefits from strategic partnerships with leading manufacturers and suppliers, which enhance its product offerings and market reach. These collaborations enable AddLife to provide cutting-edge solutions to its clients while leveraging shared resources for improved operational efficiency.
AddLife AB Earnings Call Summary
Earnings Call Date:Jul 15, 2025
(Q3-2024)
| % Change Since: |
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook with stable organic growth and positive developments such as the acquisition of BonsaiLab and improved Medtech margins. However, challenges in the Labtech segment and key markets, as well as currency impacts, were notable concerns.Q3-2024 Updates
Positive Updates
Organic Growth
The company achieved a 3% organic growth in both Labtech and Medtech segments.
Stable Cash Flow
Operating cash flow remained stable compared to last year, with improved cash conversion due to focus on inventory reduction and working capital efficiency.
Acquisition of BonsaiLab
The acquisition of BonsaiLab, a leading Spanish distributor in cell and molecular biology, was completed, contributing positively to the company's growth.
Medtech Margin Improvement
The EBITA margin in the Medtech segment increased by 7%, reaching 10.7% compared to 10% in the previous year.
Profitability Improvement Initiatives
The profitability improvement initiatives, including the closure of Camanio, are progressing according to plan, resulting in significant cost savings.
Negative Updates
Weak Labtech Instrument Sales
The Labtech segment experienced a weakness in demand for advanced high-margin instruments, leading to a lower margin of 8.9%.
Challenges in Key Markets
The U.K. and Swedish markets faced challenges due to strikes and staffing shortages, impacting sales and growth.
Slow New Product Launches
Some new product launches have been slower than expected, affecting sales targets.
Currency Impact
Currency had a negative impact of minus 3% on growth.
Company Guidance
In the third quarter of 2024, AddLife reported a 3% organic and currency-adjusted growth, maintaining a stable EBITA margin of 9.8%, despite the typically slower summer months. The company's Labtech segment experienced a slight decline in instrument sales, although consumable sales remained stable. In contrast, the Medtech segment also recorded a 3% growth, driven by higher-margin product sales and ongoing profitability improvement initiatives. Operational cash flow was stable, with a focus on inventory reduction and working capital efficiency, despite a SEK 73 million negative impact from decreased accounts payables. The acquisition of BonsaiLab contributed to the group's positive performance, bringing strong market conditions and healthy margins. Net debt remained unchanged, supported by favorable foreign exchange impacts, maintaining a leverage ratio of 3.6. The company remains committed to its established priorities of enhancing profit margins, organic growth, and strategic acquisitions while anticipating a seasonally stronger fourth quarter.AddLife AB Financial Statement Overview
Summary
AddLife AB demonstrates solid financial health with strong revenue and cash flow growth. The company has reduced its financial leverage and maintained profitability, although operational margins have faced slight pressure.Income Statement
AddLife AB shows strong revenue growth with a significant increase from 2023 to 2024. The gross profit margin is healthy, consistently above 35%. However, the EBIT margin has decreased slightly over the last few years, indicating slight pressure on operational efficiency. The company maintains a solid net profit margin, reflecting overall profitability.85
Very Positive
Balance Sheet
The balance sheet is robust with zero total debt in 2024, resulting in a strong equity position. The debt-to-equity ratio has improved significantly, indicating reduced financial leverage and potential risk. The equity ratio remains stable, showcasing a sound financial structure. However, the company should be cautious of any future liabilities that may arise.75
Positive
Cash Flow
Cash flow from operations has shown impressive growth, indicating strong operational cash generation. The free cash flow growth is substantial, highlighting efficient capital expenditure management. The operating cash flow to net income ratio is favorable, suggesting good cash conversion from profits. These factors contribute to a positive cash flow outlook.80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.44B | 10.29B | 9.69B | 9.08B | 7.99B | 5.27B |
| Gross Profit | 3.95B | 3.86B | 3.60B | 3.43B | 2.86B | 1.82B |
| EBITDA | 778.00M | 1.52B | 1.55B | 1.45B | 1.46B | 951.00M |
| Net Income | 337.00M | 252.00M | 190.00M | 480.00M | 719.00M | 517.80M |
Balance Sheet | ||||||
| Total Assets | 12.75B | 13.05B | 12.74B | 13.06B | 10.60B | 4.15B |
| Cash, Cash Equivalents and Short-Term Investments | 253.00M | 331.00M | 272.00M | 376.00M | 345.30M | 216.00M |
| Total Debt | 5.03B | 5.07B | 5.29B | 5.59B | 4.10B | 805.80M |
| Total Liabilities | 7.48B | 7.75B | 7.79B | 8.09B | 6.30B | 2.26B |
| Stockholders Equity | 5.27B | 5.31B | 4.96B | 4.97B | 4.29B | 1.88B |
Cash Flow | ||||||
| Free Cash Flow | 1.11B | 798.00M | 465.00M | 627.00M | 866.30M | 857.90M |
| Operating Cash Flow | 1.16B | 1.09B | 773.00M | 909.00M | 1.01B | 950.10M |
| Investing Cash Flow | -531.00M | -386.00M | -317.00M | -1.09B | -2.98B | -428.70M |
| Financing Cash Flow | -583.00M | -682.00M | -554.00M | 134.00M | 2.07B | -372.50M |
AddLife AB Technical Analysis
Positive
182.70
Price Trends
174.39
Positive
178.84
Positive
162.96
Positive
Market Momentum
2.37
Negative
65.96
Neutral
85.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Positive. The current price of 182.7 is above the 20-day moving average (MA) of 174.43, above the 50-day MA of 174.39, and above the 200-day MA of 162.96, indicating a bullish trend. The MACD of 2.37 indicates Negative momentum. The RSI at 65.96 is Neutral, neither overbought nor oversold. The STOCH value of 85.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALIF.B.
AddLife AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $22.05B | 65.38 | 6.27% | 0.41% | 4.56% | 185.59% | |
51 Neutral | $7.90B | -0.36 | -43.38% | 2.23% | 22.34% | -2.15% | |
| ― | kr17.63B | 64.38 | 2.76% | ― | ― | ― | |
| ― | kr18.23B | 40.30 | 3.46% | 5.52% | ― | ― | |
| ― | $2.24B | 152.10 | 20.14% | ― | ― | ― | |
| ― | $188.73M | 80.83 | 2.64% | ― | ― | ― | |
| ― | €1.48B | 62.63 | 3.34% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
SE:ALIF.B
AddLife AB
182.70
22.04
13.72%
GB:0O5H
Elekta AB
46.17
-14.93
-24.44%
GB:0YAY
Vitrolife AB
135.40
-119.61
-46.90%
BOEUF
BONESUPPORT HOLDING AB
32.96
3.64
12.41%
PXMBF
Paxman AB
3.50
0.00
0.00%
DE:0V0
Vimian Group AB
2.76
-1.14
-29.23%
AddLife AB Corporate Events
AddLife AB Reports Strong Profit Growth in H1 2025
Jul 15, 2025
AddLife AB reported a significant improvement in margins and profit for the first half of 2025, driven by strong growth in Labtech and steady demand in Medtech. The company’s strategic acquisitions, including Edge Medical Ltd., have further bolstered its performance, with a 39% increase in profit for the quarter and a 63% rise in profit after tax for the first half of the year, indicating a positive trajectory for stakeholders.
The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK178.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.